Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30872476 | 0.88 | POLB (0.48) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL38654315 | 0.85 | NPBWR1 (0.42) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL30867837 | 0.82 | MEN1 (0.57) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL30867813 | 0.81 | RET (0.44) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL38654243 | 0.81 | LMNA (0.47) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL38653818 | 0.79 | LMNA (0.46) | MEN1KMT2ALMNAPOLBMAPT | |
| SCHEMBL38653971 | 0.78 | LMNA (0.50) | MEN1KMT2ANPSR1USP2HPGD | |
| SCHEMBL38654151 | 0.77 | ACACB (0.38) | LMNAPOLBMAPTTP53 | |
| SCHEMBL38654420 | 0.77 | ACACB (0.38) | LMNAPOLBMAPTTP53 | |
| SCHEMBL38652947 | 0.77 | ACACB (0.38) | LMNAPOLBMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | MEN1 830/4885KMT2A 3439/4885NPSR1 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.